Multiple Law Firms File Securities Fraud Suits Against Insulet Corporation

Three separate law firms have initiated securities fraud class action litigation against Insulet Corporation, alleging the medical device company violated the Securities Exchange Act of 1934. The lawsuits claim Insulet made false and misleading statements while concealing defective manufacturing controls and procedures that created risks of safety violations and patient injury.

According to the complaints, these deficiencies led to two voluntary Medical Device Corrections. The first occurred on March 12, 2026, affecting Omnipod 5 Pods, and the second on May 26, 2026, affecting Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery. The Schall Law Firm further alleges that the March correction affected more products than the company publicly disclosed.

Following these disclosures, Insulet's stock price dropped significantly on March 13 and May 27, 2026. The legal actions brought by Levi & Korsinsky, LLP, Robbins Geller Rudman & Dowd LLP, and The Schall Law Firm seek to recover financial losses for shareholders who purchased securities between February 21, 2025, and May 26, 2026. Affected investors have been encouraged to contact the firms or submit documentation to the court by August 31, 2026.